Haemonetics (NYSE:HAE) Rating Lowered to Hold at StockNews.com

StockNews.com lowered shares of Haemonetics (NYSE:HAE) from a buy rating to a hold rating in a research report report published on Saturday morning.

Several other research analysts have also recently weighed in on the company. Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Needham & Company LLC reduced their price objective on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, February 7th. JMP Securities reduced their price objective on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. Barrington Research reduced their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. began coverage on Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Trading Up 0.3 %

Haemonetics stock opened at $62.47 on Friday. Haemonetics has a 12 month low of $58.80 and a 12 month high of $97.97. The business’s fifty day simple moving average is $74.18 and its two-hundred day simple moving average is $77.39. The company has a current ratio of 3.97, a quick ratio of 2.09 and a debt-to-equity ratio of 1.35. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of 24.59, a price-to-earnings-growth ratio of 0.98 and a beta of 0.39.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, equities analysts predict that Haemonetics will post 4.59 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. TD Waterhouse Canada Inc. purchased a new stake in Haemonetics in the fourth quarter worth about $25,000. Covestor Ltd increased its position in Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 439 shares in the last quarter. Whittier Trust Co. bought a new position in shares of Haemonetics in the fourth quarter worth about $62,000. Nisa Investment Advisors LLC boosted its stake in shares of Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 632 shares during the period. Finally, Parkside Financial Bank & Trust boosted its stake in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 240 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.